Jubilant Life Sciences has received the final approval from the US health regulator FDA for the Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence. The company said it has received six approvals from the regulator during the year. As on June 30, Jubilant had a total of 70 applications for Oral Solids filed in the US.